Jun 1 |
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
|
May 31 |
Takeda gets positive opinion from EU regulators for cTTP therapy
|
May 31 |
Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
|
May 23 |
ADHD diagnoses increasing, becoming an 'expanding public health concern': CDC
|
May 16 |
Takeda Canada Inc. concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY® (maribavir) for the treatment of adults with a post-transplant cytomegalovirus (CMV) infection
|
May 16 |
Takeda’s dengue vaccine obtains WHO prequalification
|
May 15 |
Takeda dengue vaccine gets WHO clearance
|
May 14 |
Update: Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute
|
May 14 |
Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute
|
May 14 |
Scilex wins court approval for Takeda settlement
|